MIR17HG and B-cell non-Hodgkin lymphoma: Of note, MIR17HG was targeted in SC-1 by a focal genomic amplification at 13q21 (Supplementary Figure S3) and showed enhanced expression (Supplementary Table S1), indicating oncogenic activity of this micro-RNA gene in SC-1 cells and triple-hit B-cell lymphoma.